Real-world comparative effectiveness and safety of tofacitinib and baricitinib in patients with rheumatoid arthritis.

ABSTRACT:

Objective

To compare the efficacy and safety of tofacitinib and baricitinib in patients with RA in a real-world setting.

Methods

A total of 242 patients with RA who were treated with tofacitinib (n = 161) or baricitinib (n = 81) were enrolled. We evaluated efficacy and safety between tofacitinib and baricitinib using multivariable analyses to avoid confounding. Their clinical disease activity and AEs were evaluated for 24 weeks.

Results

The mean (SD) DAS28-ESR change from baseline to 24 weeks was 1.57 (1.55) (tofacitinib) and 1.46 (1.36) (baricitinib). There was no significant difference in the clinical response between the two groups (adjusted mean difference, 0.04; 95% CI, -0.35 to 0.28). The efficacy was not significantly changed in the patients without concomitant

SUBMITTER: Iwamoto N 

PROVIDER: S-EPMC8299678 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature